S100A11 and prostate cancer: The up-regulation of S100A11 has been reported in various cancers [9], such as laryngeal [10], breast [11], lung [12–13], gastric [14], colorectal [15], pancreatic [16], and prostate cancers [17], and has frequently been associated with cancer progression, implicating its oncogenic role [10–17].